TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
1.690
+0.190 (12.67%)
At close: Mar 9, 2026, 4:00 PM EDT
1.670
-0.020 (-1.18%)
After-hours: Mar 9, 2026, 7:58 PM EDT
TuHURA Biosciences Employees
TuHURA Biosciences had 19 employees as of December 31, 2024. The number of employees increased by 18 or 1,800.00% compared to the previous year.
Employees
19
Change (1Y)
18
Growth (1Y)
1,800.00%
Revenue / Employee
n/a
Profits / Employee
-$1,541,833
Market Cap
102.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Verrica Pharmaceuticals | 71 |
| PMV Pharmaceuticals | 47 |
| Pyxis Oncology | 44 |
| Vivani Medical | 37 |
| Cognition Therapeutics | 28 |
| iBio, Inc. | 20 |
| MAIA Biotechnology | 13 |
| Dogwood Therapeutics | 12 |
HURA News
- 10 days ago - TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 13 days ago - TuHURA Biosciences Announces Participation in Upcoming Investor Conferences - PRNewsWire
- 20 days ago - TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers - PRNewsWire
- 25 days ago - TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - PRNewsWire
- 5 weeks ago - TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - PRNewsWire
- 3 months ago - TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone - PRNewsWire
- 3 months ago - TuHURA Biosciences Provides Corporate Update Following Recent Financing - PRNewsWire
- 3 months ago - TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering - PRNewsWire